Indeed, the correlation of Trop-2 expression with disease and/or clinical outcome in multiple tumor types, and the lower expression in normal adult tissues compared to several pathological counterpart (38–41), underscores the potential benefit of targeting Trop-2 to fill an unmet need in cancer treatment. Here, TACSTD2 is linked to neoplasm.